WO1996010403A1 - Use of retinoid glycosides in topical pharmaceutical compositions - Google Patents
Use of retinoid glycosides in topical pharmaceutical compositions Download PDFInfo
- Publication number
- WO1996010403A1 WO1996010403A1 PCT/US1995/011314 US9511314W WO9610403A1 WO 1996010403 A1 WO1996010403 A1 WO 1996010403A1 US 9511314 W US9511314 W US 9511314W WO 9610403 A1 WO9610403 A1 WO 9610403A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- present
- concentration
- group
- Prior art date
Links
- 239000012049 topical pharmaceutical composition Substances 0.000 title claims description 7
- -1 retinoid glycosides Chemical class 0.000 title description 5
- 229930182470 glycoside Natural products 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 38
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims abstract description 12
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 3
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 3
- 206010000496 acne Diseases 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 206010040954 Skin wrinkling Diseases 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical class OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 abstract description 11
- 206010013774 Dry eye Diseases 0.000 abstract description 6
- 229930002330 retinoic acid Natural products 0.000 abstract description 5
- 229960001727 tretinoin Drugs 0.000 abstract description 5
- 208000017520 skin disease Diseases 0.000 abstract description 4
- 230000029663 wound healing Effects 0.000 abstract description 3
- 230000009759 skin aging Effects 0.000 abstract 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 18
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 235000019155 vitamin A Nutrition 0.000 description 10
- 239000011719 vitamin A Substances 0.000 description 10
- 229940045997 vitamin a Drugs 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- 150000004492 retinoid derivatives Chemical class 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000002156 mixing Methods 0.000 description 5
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000003560 epithelium corneal Anatomy 0.000 description 4
- 210000002175 goblet cell Anatomy 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 229960003471 retinol Drugs 0.000 description 4
- 235000020944 retinol Nutrition 0.000 description 4
- 239000011607 retinol Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 102000029752 retinol binding Human genes 0.000 description 3
- 108091000053 retinol binding Proteins 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010021135 Hypovitaminosis Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 210000004561 lacrimal apparatus Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000473 propyl gallate Substances 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 229940075579 propyl gallate Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- MTGFYEHKPMOVNE-NEFMKCFNSA-N 1-O-all-trans-retinoyl-beta-glucuronic acid Chemical compound O([C@H]1[C@@H]([C@@H](O)[C@H](O)[C@H](O1)C(O)=O)O)C(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C MTGFYEHKPMOVNE-NEFMKCFNSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920002306 Glycocalyx Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 229940082649 blood substitutes and perfusion irrigating solutions Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 229940073669 ceteareth 20 Drugs 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 210000004517 glycocalyx Anatomy 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000013010 irrigating solution Substances 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004175 meibomian gland Anatomy 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 208000015200 ocular cicatricial pemphigoid Diseases 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940100458 steareth-21 Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 238000009901 transfer hydrogenation reaction Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 208000005494 xerophthalmia Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
Definitions
- the present invention relates to the use of certain retinoic acid analogues as therapeutic agents, particularly as wound healing agents, in irrigating solutions, and for the treatment of skin disorders and dry eye syndromes.
- dry eye syndromes includes but is not limited to: ocular cicatricial pemphigoid, Stevens- Johnson Syndrome, xerophthalmia, hypovitaminosis A, trachoma, and trauma to the conjunctiva.
- the retinoic acid analogues of the present invention include retinoyl ⁇ -glucuronide and retinoyl ⁇ -glucose and their oxidative degradation products.
- the present invention also relates to topical pharmaceutical compositions comprising such compounds as well as methods for their use.
- the Tseng article describes experiments in which an ointment containing Vitamin A is utilized to treat dry eye disorders associated with Sjogren's Syndrome and Stevens- Johnson Syndrome.
- the tear film is thought to be composed of three layers: an outer, lipid layer secreted by the meibomian glands; a middle, aqueous layer secreted by the main and accessory lacrimal glands; and an inner, mucin layer which is in direct contact with the conjunctival and corneal epithelium and which is secreted by the conjunctival goblet cells.
- the functions of tears and the corneal epithelium are three-fold: to form a smooth refractive corneal surface; to form a barrier between the environment and the stroma; and to provide a wettable, lubricated surface to allow comfortable blinking.
- the microvilli on the surfaces of the most superficial epithelial cells are covered with a glycocalyx that interacts with the mucin layer of the tear film.
- Deficient functioning of the different layers of tear film may cause different symptoms of dry eye syndromes. For example, cicatricial pemphigoid and Stevens-
- Johnson Syndrome are two disorders usually described as mucin deficiency dry eye syndromes.
- a classic example of mucin deficiency caused by degeneration or loss of goblet cells is hypo-vitaminosis A. This can be induced experimentally in laboratory animals and is found endemically in developing countries.
- Vitamin A is necessary for maturation of goblet cells, and that it also plays an essential role in the biosynthesis of cell surface glycoconjugates. In fact, it appears that Vitamin A is required for the normal synthesis of cell surface glycoconjugates in the corneal epithelium. Non- wetting of the ocular surface, one of the signs of Vitamin A deficiency, is generally attributable to the loss of mucous glycoproteins.
- Vitamin A is bound to retinol binding protein (RBP).
- RBP retinol binding protein
- Retinoic acid (the acid form of Vitamin A) is also effective in treating disorders of the eye. This may be by enhancing the healing rate of experimentally-induced corneal epithelial wounds and speeding corneal healing when topically applied to xerophthalmic patients; however, both retinoic acid and Vitamin A are very insoluble in water, and both are highly susceptible to oxidation in the presence of oxygen or in air. These compounds have therefore been primarily formulated in petroleum-based ointments.
- Varma discloses aqueous ophthalmic solutions comprising retinol and/or derivatives or precursors thereof, which are solubilized in water using certain non-ionic surfactants and hydroxypropyl methylcellulose.
- Gressel et al. - I disclose topical ophthalmic compositions comprising low concentrations of one or more retinoids, which include near and remote analogues and functional derivatives of retinoic acid which may be biotransf ormed into the active form of the retinoid.
- compositions comprising low concentrations of microfine particles of one or more retinoids of the type disclosed in Gressel et al. - I.
- antioxidants are preferably included for purposes of stability.
- these soluble and stable compounds of the present invention are useful as therapeutic agents to treat a variety of diseases, such as skin disorders, and dry eye and related ailments. These compounds can be used singly or in combination.
- the retinoic acid analogues of the present invention include the racemic and isomeric forms of the compounds of formula (I):
- DCC dicyclohexylcarbodiimide
- compositions of the present invention are primarily intended for the treatment of ocular surface disorders, particularly dry eye syndromes, inflammation, wound healing and related ailments. Symptoms include, without limitation, foreign body sensation, burning and hyperemia.
- the retinoids of the present invention are formulated, either singly or in combination, at a concentration between about 0.0001 and about 2.0 percent by weight (wt%), and preferably at a concentration between about 0.01 and about 0.5 wt%. Depending on the particular compounds, it is most preferable to formulate the retinoids at a concentration of about 0.1 wt%.
- compositions of the present invention are intended for the treatment of skin disorders, such as acne, psoriasis and skin-wrinkling (skin-ageing), and as an aid in wound healing.
- skin disorders such as acne, psoriasis and skin-wrinkling (skin-ageing)
- the retinoids of the present invention are formulated, either singly or in combination, at a concentration between about 0.001 and about 2 percent by weight (wt%), preferably between about 0.01 and about 1 wt%.
- the retinoids it is most preferable to formulate the retinoids at a concentration of about 0.5 wt%.
- a dose of one or two drops of a compositions of the present invention is generally administered two to four times per day, although dosing may be more or less frequent, depending on the severity of the disease. Frequency of dosing is variably dependent upon severity; in severe cases, dosing may occur twelve to sixteen or more times per day.
- the retinoids are usually applied topically to the affected area as needed, usually two to four times per day, although administration may be more or less frequent, depending on the severity of the disease.
- the ophthalmic compositions of the present invention may additionally contain sodium chloride or other suitable tonicity adjusting agents, including but not limited to: potassium chloride, calcium chloride, mannitol, and glycerin.
- Such tonicity adjusting agents are typically used at a concentration between about 75 and about 154 mmol/L so that the resultant osmolality or the composition is between about 200 and about 350 milliOsmoles/kilogram (mOsm/kg). It is preferred that these compositions have an osmolality between about 260 and about 330 mOsm/kg.
- the ophthalmic compositions of the present invention will generally have a pH between about 4.0 and about 9.5, preferably between about 5.0 and 8.5.
- the ophthalmic compositions of the present invention may additionally contain mucomimetic polymers and lubricating agents for increased comfort and sustained duration in the eye.
- mucomimetic polymers and lubricating agents for increased comfort and sustained duration in the eye.
- examples of the above include: Dextran; cellulose derivatives, e.g., hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose; polyvinyl yrrolidone; and polyethylene glyco ls.
- these polymers are present in the compositions of the present invention at a concentration between about 0.05 and about 5.0 wt%, preferably between about 0.1 and about 2.0 wt%.
- Examples 1 and 2 illustrate typical compositions of the present invention.
- compositions useful in the present invention are typical examples. These compositions may be formulated in accordance with procedures known to those skilled in the art.
- Hydroxypropyl methyl cellulose, Carbomer 934P, Carboxy methyl cellulose or sodium hyaluronate is dissolved in purified water followed by the addition of other excipients.
- the pH of the batch is adjusted, and the retinoid is then dissolved into the solution and added to the batch.
- the oil phase of the emulsion is prepared by combining and heating the lipophilic components (stearic acid, white wax, isopropyl palmitate, emulsifying wax and polysorbate 60). Propyl gallate and butylated hydroxytoluene are then dissolved in melted
- the temperature is maintained between 70° and 85° C.
- the aqueous phase is prepared by the addition of the water soluble components of the formulation, and the pH is adjusted. The temperature is maintained by heating the batch to 70° - 85° C.
- compositions useful in the present invention are additional examples of dermatological compositions useful in the present invention:
- the oil phase of the emulsion is prepared by mixing together and heating the lipophilic components (such as petrolatum, mineral oil, Dimethicone, cetyl alcohol, stearyl alcohol, cetearyl alcohol (and) ceteareth-20, glyceryl stearate (and) PEG- 100 stearate, steareth-21 and cyclomethicone). Propyl gallate and butylated hydroxytoluene are then dissolved in with the melted components. The temperature is maintained between 70° and 85° C.
- the lipophilic components such as petrolatum, mineral oil, Dimethicone, cetyl alcohol, stearyl alcohol, cetearyl alcohol (and) ceteareth-20, glyceryl stearate (and) PEG- 100 stearate, steareth-21 and cyclomethicone.
- the aqueous phase is prepared by dispersing Carbomer 941 in an aliquot of purified water, followed by the addition of the water solu omponents of the formulation and the pH adjusted. The temperature is maintained by heating the batch to 70° - 85° C.
- the retinoid is separately dissolved in a portion of purified water, and then added to the main batch. Final batch volume djusted with purified water.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Certain stable analogues of retinoic acid are found to be useful in the treatment of dry eye and related aliments, and skin disorders such as acne, psoriasis, skin aging and wound healing. These compounds are much more soluble than retinoic acid, and may therefore be formulated in standard.
Description
USE OF RETINOID GLYCOSIDES IN TOPICAL PHARMACEUTICAL COMPOSITIONS
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to the use of certain retinoic acid analogues as therapeutic agents, particularly as wound healing agents, in irrigating solutions, and for the treatment of skin disorders and dry eye syndromes. As used herein, the term "dry eye syndromes" includes but is not limited to: ocular cicatricial pemphigoid, Stevens- Johnson Syndrome, xerophthalmia, hypovitaminosis A, trachoma, and trauma to the conjunctiva. The retinoic acid analogues of the present invention include retinoyl β-glucuronide and retinoyl β-glucose and their oxidative degradation products. The present invention also relates to topical pharmaceutical compositions comprising such compounds as well as methods for their use.
2. Discussion of Related Art
Dry eye symptoms and related eye ailments, including more transitory discomfort, are among the most commonly reported medical complaints. these ailments are well known in the scientific and patent literature. The following patents are incorporated by reference herein to the extent that they provide additional bac kround on the ailments and recognized indications for their relief: US 4,039,662; US 3
3; US 3,920,810; US
3,843,782; US 4,131,651; US 4,826,871; and Belgian Patent 844,544. A further description of the physical manifestations associated with dry eye c.isorders is seen in a scientific paper presented by Scheffer Chuei-Goong Tseng at the Science Writers Seminar in Ophthalmology, sponsored by Research to Prevent Blindness, Inc., held in Washington DC from September 30 to October 3, 1984: Tseng, "Topical Vitamin A Treatment for
Dry Eye Disorders," pages 1-6 (1984). The Tseng article describes experiments in which
an ointment containing Vitamin A is utilized to treat dry eye disorders associated with Sjogren's Syndrome and Stevens- Johnson Syndrome.
The tear film is thought to be composed of three layers: an outer, lipid layer secreted by the meibomian glands; a middle, aqueous layer secreted by the main and accessory lacrimal glands; and an inner, mucin layer which is in direct contact with the conjunctival and corneal epithelium and which is secreted by the conjunctival goblet cells. The functions of tears and the corneal epithelium are three-fold: to form a smooth refractive corneal surface; to form a barrier between the environment and the stroma; and to provide a wettable, lubricated surface to allow comfortable blinking. The microvilli on the surfaces of the most superficial epithelial cells are covered with a glycocalyx that interacts with the mucin layer of the tear film.
Deficient functioning of the different layers of tear film may cause different symptoms of dry eye syndromes. For example, cicatricial pemphigoid and Stevens-
Johnson Syndrome are two disorders usually described as mucin deficiency dry eye syndromes. A classic example of mucin deficiency caused by degeneration or loss of goblet cells is hypo-vitaminosis A. This can be induced experimentally in laboratory animals and is found endemically in developing countries.
It appears that Vitamin A is necessary for maturation of goblet cells, and that it also plays an essential role in the biosynthesis of cell surface glycoconjugates. In fact, it appears that Vitamin A is required for the normal synthesis of cell surface glycoconjugates in the corneal epithelium. Non- wetting of the ocular surface, one of the signs of Vitamin A deficiency, is generally attributable to the loss of mucous glycoproteins. Although
Applicants do not wish to be bound to any particular theory, the most likely mechanism for the delivery of retinol to the cornea is by uptake from circulation and/or from tears. Given the importance of Vitamin A to the ocular surface, its secretion by the lacrimal gland into tear fluid has obvious physiological implications in the maturation and maintenance of normal goblet cell function. Within the cell, Vitamin A is bound to retinol binding protein (RBP). The binding of retinol to cellular RBP is greatly impaired in
corneas of Vitamin A-deficient rabbits. See, for example, Berman, E., Biochemistry of the Eye. Plenum Press: NY; 1991, pp. 93-95. Vitamin A is an essential component in the chemical process of vision. Among the major function of retinol in corneal epithelium, two functions have been clearly established: control of keratitis expression; and synthesis of glycoconjugates.
Retinoic acid (the acid form of Vitamin A) is also effective in treating disorders of the eye. This may be by enhancing the healing rate of experimentally-induced corneal epithelial wounds and speeding corneal healing when topically applied to xerophthalmic patients; however, both retinoic acid and Vitamin A are very insoluble in water, and both are highly susceptible to oxidation in the presence of oxygen or in air. These compounds have therefore been primarily formulated in petroleum-based ointments.
Ointments are greasy, inconvenient, and often interfere with vision; therefore, several attempts have been made in the past to overcome these solubility and
problems. Such attempts include those described in US 5,032392 (Varma), US 4,826,871 (Gressel et al. - I), and US 4,966,773 (Gressel et al. - II). Varma discloses aqueous ophthalmic solutions comprising retinol and/or derivatives or precursors thereof, which are solubilized in water using certain non-ionic surfactants and hydroxypropyl methylcellulose. Gressel et al. - I disclose topical ophthalmic compositions comprising low concentrations of one or more retinoids, which include near and remote analogues and functional derivatives of retinoic acid which may be biotransf ormed into the active form of the retinoid. Gressel et al. - II disclose topical ophthalmic compositions comprising low concentrations of microfine particles of one or more retinoids of the type disclosed in Gressel et al. - I. In the compositions of Varma and Gressel et al. - I and II, antioxidants are preferably included for purposes of stability.
SUMMARY OF THE INVENTION It has now been surprisingly found that certain novel structural analogues of retinoids have significantly greater aqueous solubility and stability than retinoic acid and
other, known retinoic acid analogues. This permits the compounds of the present invention to be formulated in standard pharmaceutical compositions and dosage forms such as solutions, semi-solids, aerosol, in lyophihzed form, and including aqueous compositions.
It has also surprisingly been found that these soluble and stable compounds of the present invention are useful as therapeutic agents to treat a variety of diseases, such as skin disorders, and dry eye and related ailments. These compounds can be used singly or in combination.
DETAILED DESCRIPTION OF THE INVENTION
The retinoic acid analogues of the present invention include the racemic and isomeric forms of the compounds of formula (I):
Such compounds are described in PCT US93/10998 (Curley). Methods for preparation of these compounds are also disclosed in the Curley application.
PCT US93/10998 is hereby incorporated by reference to the extent it describes the compounds of formula (I) and the methods for their preparation. For purposes of this specification, the terms "retinoids" or "retinoids of the present invention" shall refer to the compounds of formula (I) unless the context clearly indicates otherwise.
The compounds of the present invention can also be prepared by the efficient alternative synthetic route such as shown in Schemes 1 and 2, shown below. Derivatives of either benzyl-tri-o-benzyl-β-D-glucuronate (or glucoside) (Scheme 1) or
benzyl-p-aminophenyl-tri-o-benzyl-β-D-glucuronate (or glucoside) (Scheme 2) and retinoic acid are reacted together in the presence of a condensing agent such as
dicyclohexylcarbodiimide (DCC). This reaction is followed by catalytic transfer hydrogenation using ammonium formate palladium-on-carbon as a catalyst to yield the desired retinoid listed in Tables 1 and 2.
The compositions of the present invention are primarily intended for the treatment of ocular surface disorders, particularly dry eye syndromes, inflammation, wound healing and related ailments. Symptoms include, without limitation, foreign body sensation, burning and hyperemia. For ophthalmic use, the retinoids of the present invention are formulated, either singly or in combination, at a concentration between about 0.0001 and about 2.0 percent by weight (wt%), and preferably at a concentration between about 0.01 and about 0.5 wt%. Depending on the particular compounds, it is most preferable to formulate the retinoids at a concentration of about 0.1 wt%.
In addition, the compositions of the present invention are intended for the treatment of skin disorders, such as acne, psoriasis and skin-wrinkling (skin-ageing), and as an aid in wound healing. For treatment of such disorders, the retinoids of the present invention are formulated, either singly or in combination, at a concentration between about 0.001 and about 2 percent by weight (wt%), preferably between about 0.01 and about 1 wt%.
Depending on the particular compounds, it is most preferable to formulate the retinoids at a concentration of about 0.5 wt%.
For the treatment of ocular surface disorders, a dose of one or two drops of a compositions of the present invention is generally administered two to four times per day, although dosing may be more or less frequent, depending on the severity of the disease. Frequency of dosing is variably dependent upon severity; in severe cases, dosing may occur twelve to sixteen or more times per day. For dermatological use, the retinoids are usually applied topically to the affected area as needed, usually two to four times per day, although administration may be more or less frequent, depending on the severity of the disease.
The ophthalmic compositions of the present invention may additionally contain sodium chloride or other suitable tonicity adjusting agents, including but not limited to: potassium chloride, calcium chloride, mannitol, and glycerin. Such tonicity adjusting agents are typically used at a concentration between about 75 and about 154 mmol/L so that the resultant osmolality or the composition is between about 200 and about 350 milliOsmoles/kilogram (mOsm/kg). It is preferred that these compositions have an osmolality between about 260 and about 330 mOsm/kg. The ophthalmic compositions of the present invention will generally have a pH between about 4.0 and about 9.5, preferably between about 5.0 and 8.5.
The ophthalmic compositions of the present invention may additionally contain mucomimetic polymers and lubricating agents for increased comfort and sustained duration in the eye. Examples of the above include: Dextran; cellulose derivatives, e.g., hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose; polyvinyl
yrrolidone; and polyethylene glyco ls. In general, these polymers are present in the compositions of the present invention at a concentration between about 0.05 and about 5.0 wt%, preferably between about 0.1 and about 2.0 wt%. The following Examples 1 and 2 illustrate typical compositions of the present invention.
EXAMPLE 1
The following are typical examples of ophthalmic compositions useful in the present invention. These compositions may be formulated in accordance with procedures known to those skilled in the art.
Preparation:
All the excipients are dissolved into an aliquot of purified water, the retinoid is then dissolved in the batch, and the pH adjusted. Purified water is then added to bring the final volume to 100%.
EXAMPLE 2
The following are additional examples of ophthalmic compositions useful in the present invention.
Preparation:
All excipients are dissolved into an aliquot of purified water. The retinoid is then dissolved into this solution, and the pH of the solution is adjusted. Purified water is then added to bring the batch volume to 100%.
EXAMPLE 3
The following are additional examples of viscous compositions useful in the present invention:
Preparation:
Hydroxypropyl methyl cellulose, Carbomer 934P, Carboxy methyl cellulose or sodium hyaluronate is dissolved in purified water followed by the addition of other excipients. The pH of the batch is adjusted, and the retinoid is then dissolved into the solution and added to the batch.
EXAMPLE 4 The following are additional examples of dermatological compositions useful in the present invention:
Preparation:
The oil phase of the emulsion is prepared by combining and heating the lipophilic components (stearic acid, white wax, isopropyl palmitate, emulsifying wax and polysorbate 60). Propyl gallate and butylated hydroxytoluene are then dissolved in melted
components. The temperature is maintained between 70° and 85° C.
The aqueous phase is prepared by the addition of the water soluble components of the formulation, and the pH is adjusted. The temperature is maintained by heating the batch to 70° - 85° C.
Preparation of emulsion: both the oil phase and aqueous phases are combined at 70° - 85° C temperature with continuous mixing. The batch is cooled to room temperature with mixing, the pH is then adjusted to the desired level using citric acid and/or NaOH. The retinoid is then separately dissolved in a portion of purified water and added to the main batch. Final batch volume is adjusted with purified water. EXAMPLE 5
The following are additional examples of dermatological compositions useful in the present invention:
Preparation:
The oil phase of the emulsion is prepared by mixing together and heating the lipophilic components (such as petrolatum, mineral oil, Dimethicone, cetyl alcohol, stearyl alcohol, cetearyl alcohol (and) ceteareth-20, glyceryl stearate (and) PEG- 100 stearate, steareth-21 and cyclomethicone). Propyl gallate and butylated hydroxytoluene are then dissolved in with the melted components. The temperature is maintained between 70° and 85° C.
The aqueous phase is prepared by dispersing Carbomer 941 in an aliquot of purified water, followed by the addition of the water solu omponents of the formulation and the pH adjusted. The temperature is maintained by heating the batch to 70° - 85° C.
Preparation of emulsion: both the oil phase and aqueous phases are combined at 70° - 85° C temperature with continuous mixing. The batch is then cooled to room temperature with mixing. The pH is then adjusted to desired level using citric acid and/or
NaOH. The retinoid is separately dissolved in a portion of purified water, and then added to the main batch. Final batch volume djusted with purified water.
The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.
Claims
1. A topical pharmaceutical composition, comprising a pharmaceutically acceptable vehicle and a pharmaceutically effective amount of the racemic or isomeric forms of a compound of formula:
2. The topical pharmaceutical composition of claim 1, wherein the compound of formula (I) is present at a concentration between about 0.001 and about 2.0 wt%.
3. The topical pharmaceutical composition of claim 2, wherein the compound of formula (I) is present at a concentration between about 0.01 and about 0.5 wt%.
4. The topical pharmaceutical composition of claim 3, wherein the compound of formula (I) is present at a concentration of about 0.5 wt%.
5. The pharmaceutical composition of claim 1, wherein the compound of formula (I) is selected from the group consisting of:
6. The pharmaceutical composition of claim 5, wherein the compound of formula (I) is selected from the group consisting of:
7. An ophthalmic composition comprising an ophthalmically acceptable vehicle and an ophthalmically acceptable amount of the racemic or isomeric forms of a compound of formula:
8. The ophthalmic composition of claim 7, wherein the compound of formula (I) is present at a concentration between about 0.0001 and about 2.0 wt%.
9. The ophthalmic composition of claim 8, wherein the compound of formula (I) is present at a concentration between about 0.01 and about 0.5 wt%.
10. The ophthalmic composition of claim 9, wherein the compound of formula (I) is present at a concentration of about 0.1 wt%.
11. The ophthalmic composition of claim 7, wherein the compound of formula (I) is selected from the group consisting of:
12. The ophthalmic composition of claim 11, wherein the compound of formula (I) is selected from the group consisting of:
13. A method for treating ocular surface disorders, comprising topically applying to an affected eye an ophthalmically effective amount of the racemic or isomeric forms of a compound of formula:
14. The method of claim 13, wherein the compound of formula (I) is present at a concentration between about 0.0001 and about 2.0 wt%.
15. The method of claim 14, wherein the compound of formula (I) is present at a concentration between about 0.01 and about 0.5 wt%.
16. The method of claim 15, wherein the compound of formula (I) is present at a concentration of about 0.1 wt%.
17. The method of claim 13, wherein the ocular surface disorder is selected from the group consisting of dry eye syndromes.
18. The method of claim 13, wherein the compound of formula (I) is selected from the group consisting of:
19. The method of claim 18, wherein the compound of formula (I) is selected from the group consisting of:
20. A method for treating dermatological disorders, comprising topically applying to an affected area a pharmaceutically effective amount of the racemic or isomeric forms of a compound of formula:
21. The method of claim 20, wherein the compound of formula (I) is present at a concentration between about 0.001 and about 2.0 wt%.
22. The method of claim 21, wherein the compound of formula (I) is present at a concentration between about 0.01 and about 0.5 wt%.
23. The method of claim 22, wherein the compound of formula (I) is present at a concentration of about 0.5 wt%.
24. The method of claim 20, wherein the dermatological disorder is selected from the group consisting of: acne, psoriasis and skin- wrinkling or ageing.
25. The method of claim 24, wherein the compound of formula (I) is selected from the group consisting of:
26. The method of claim 25, wherein the compound of formula (I) is selected from the group consisting of:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU36276/95A AU3627695A (en) | 1994-09-30 | 1995-09-07 | Use of retinoid glycosides in topical pharmaceutical compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31563994A | 1994-09-30 | 1994-09-30 | |
US08/315,639 | 1994-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996010403A1 true WO1996010403A1 (en) | 1996-04-11 |
Family
ID=23225371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/011314 WO1996010403A1 (en) | 1994-09-30 | 1995-09-07 | Use of retinoid glycosides in topical pharmaceutical compositions |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3627695A (en) |
WO (1) | WO1996010403A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0818194A2 (en) * | 1996-06-14 | 1998-01-14 | McNEIL-PPC, INC. | Lubricant compositions that are spreadable onto and adherable to biomembranes, method of making and use thereof |
WO2000058325A1 (en) * | 1999-03-31 | 2000-10-05 | Pierre Fabre Dermo-Cosmetique | Bioprecursors of a retinoic derivative and pharmaceutical and/or cosmetic compositions |
WO2002049613A2 (en) * | 2000-12-19 | 2002-06-27 | Bausch & Lomb Incorporated | Method for enhancing integrity of epithelium using retinoic acid |
EP2035015A2 (en) * | 2006-05-01 | 2009-03-18 | Riolan Technologies, Inc. | Compositions, methods, and kits for treating dry eye |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4966773A (en) * | 1986-11-25 | 1990-10-30 | Alcon Laboratories, Inc. | Topical ophthalmic compositions containing microfine retinoid particles |
US5037655A (en) * | 1990-04-18 | 1991-08-06 | Giovanoni Richard L | Method of stabilizing tretinoin |
EP0472225A2 (en) * | 1985-12-11 | 1992-02-26 | L V M H Recherche | Hydrated lammelar lipidic phases or liposomes containing tretinoid |
FR2666015A1 (en) * | 1990-08-23 | 1992-02-28 | Oreal | Cosmetic and/or dermopharmaceutical composition containing retinoic acid or its derivatives, intended for treatment of the hair or scalp |
WO1994011030A1 (en) * | 1992-11-13 | 1994-05-26 | The Ohio State University Research Foundation | C-glycoside analogues of n-(4-hydroxyphenyl)retinamide-o-glucuronide |
WO1995009862A1 (en) * | 1993-10-06 | 1995-04-13 | Ciba-Geigy Ag | Water-soluble retinoids |
-
1995
- 1995-09-07 AU AU36276/95A patent/AU3627695A/en not_active Abandoned
- 1995-09-07 WO PCT/US1995/011314 patent/WO1996010403A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0472225A2 (en) * | 1985-12-11 | 1992-02-26 | L V M H Recherche | Hydrated lammelar lipidic phases or liposomes containing tretinoid |
US4966773A (en) * | 1986-11-25 | 1990-10-30 | Alcon Laboratories, Inc. | Topical ophthalmic compositions containing microfine retinoid particles |
US5037655A (en) * | 1990-04-18 | 1991-08-06 | Giovanoni Richard L | Method of stabilizing tretinoin |
FR2666015A1 (en) * | 1990-08-23 | 1992-02-28 | Oreal | Cosmetic and/or dermopharmaceutical composition containing retinoic acid or its derivatives, intended for treatment of the hair or scalp |
WO1994011030A1 (en) * | 1992-11-13 | 1994-05-26 | The Ohio State University Research Foundation | C-glycoside analogues of n-(4-hydroxyphenyl)retinamide-o-glucuronide |
WO1995009862A1 (en) * | 1993-10-06 | 1995-04-13 | Ciba-Geigy Ag | Water-soluble retinoids |
Non-Patent Citations (2)
Title |
---|
M.J. PANIGOT ET AL.: "Preparation of 4-retinamidophenyl- and 4-retinamidobenzyl-c-glycosyl and c-glucuronosyl analogs of the glucuronide of 4-hydroxyphenylretinamide as potential stable cancer chemopreventive agents.", J. CARBOHYDR. CHEM., vol. 13, no. 2, pages 303 - 312 * |
M.J. ROBARGE ET AL.: "N-linked analogs of retinoid O-glucuronides: potential cancer chemopreventive/chemotherapeutic agents.", MED. CHEM. LETT., vol. 4, no. 17, pages 2117 - 2122 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0818194A2 (en) * | 1996-06-14 | 1998-01-14 | McNEIL-PPC, INC. | Lubricant compositions that are spreadable onto and adherable to biomembranes, method of making and use thereof |
EP0818194A3 (en) * | 1996-06-14 | 1998-07-22 | McNEIL-PPC, INC. | Lubricant compositions that are spreadable onto and adherable to biomembranes, method of making and use thereof |
WO2000058325A1 (en) * | 1999-03-31 | 2000-10-05 | Pierre Fabre Dermo-Cosmetique | Bioprecursors of a retinoic derivative and pharmaceutical and/or cosmetic compositions |
FR2791679A1 (en) * | 1999-03-31 | 2000-10-06 | Fabre Pierre Dermo Cosmetique | BIOPRECURSORS CAPABLE OF RELEASING A RETINOIC DERIVATIVE BY TAKING ADVANTAGE OF THE ENZYMATIC ACTIVITY OF THE SKIN SURFACE AND PHARMACEUTICAL AND / OR COSMETIC COMPOSITIONS |
WO2002049613A2 (en) * | 2000-12-19 | 2002-06-27 | Bausch & Lomb Incorporated | Method for enhancing integrity of epithelium using retinoic acid |
WO2002049613A3 (en) * | 2000-12-19 | 2003-01-16 | Bausch & Lomb | Method for enhancing integrity of epithelium using retinoic acid |
US6787131B2 (en) | 2000-12-19 | 2004-09-07 | Bausch & Lomb Incorporated | Method for enhancing integrity of epithelium using retinoic acid |
EP2035015A2 (en) * | 2006-05-01 | 2009-03-18 | Riolan Technologies, Inc. | Compositions, methods, and kits for treating dry eye |
EP2035015A4 (en) * | 2006-05-01 | 2009-11-11 | Riolan Technologies Inc | Compositions, methods, and kits for treating dry eye |
Also Published As
Publication number | Publication date |
---|---|
AU3627695A (en) | 1996-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9119827B2 (en) | Ophthalmic composition | |
US4976969A (en) | Ophthalmic solution comprising iodine-polyvinylpyrrolidone complex | |
CA2784492C (en) | Non-irritating ophthalmic povidone-iodine compositions | |
EP1553953B1 (en) | Method and composition containing latanoprost for treating ocular hypertension and glaucoma | |
US8906427B2 (en) | Treatment for meibomian gland dysfunction or obstruction | |
US6114319A (en) | Compositions containing difluprednate | |
US20120128763A1 (en) | Lubricant for the ocular surface | |
EP2389939A1 (en) | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions | |
JP2003523925A (en) | Ophthalmic solution containing tetracycline for topical treatment of dry eye disease | |
US6159930A (en) | Pharmaceutical composition comprising albumin as an active ingredient | |
JP2007528897A (en) | Lubricant for ocular surface | |
JP2811036B2 (en) | Vitamin E eye drops | |
Herbort et al. | Topical retinoic acid in dysplastic and metaplastic keratinization of corneoconjunctival epithelium | |
US6659985B2 (en) | Method to use transdermal administration of androgens to the adnexa of the eye | |
JPH1129483A (en) | Composition containing difluprednate | |
WO2012100109A2 (en) | Therapeutic eye drop comprising doxycycline and a stabilizer | |
WO1996010403A1 (en) | Use of retinoid glycosides in topical pharmaceutical compositions | |
AU2017235979B2 (en) | Non-irritating ophthalmic povidone-iodine compositions | |
KeeS | Johnson Syndrome are two disorders usually described as mucin deficiency dry eye syndromes. A classic example of mucin deficiency caused by degeneration or loss of goblet cells is hypo-vitaminosis A. This can be induced experimentally in laboratory animals and is found endemically in developing countries. It appears that Vitamin A is necessary for maturation of goblet cells, and that it | |
WO2005100362A1 (en) | Liquid external preparation containing pranoprofen | |
JPH10194968A (en) | Ophthalmic solution compounded with vitamin k and vitamin k | |
NZ751915B2 (en) | Non-irritating ophthalmic povidone-iodine compositions | |
ZA200607607B (en) | Lubricant for the ocular surface |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |